Log in

Relevant bibliographies by topics / Ying han dui zhao du wu

Contents

Journal articles
Books

Academic literature on the topic 'Ying han dui zhao du wu'

Author: Grafiati

Published: 11 December 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ying han dui zhao du wu.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ying han dui zhao du wu"

1

Li, Xiao-Ling, Hai-Ying Yu, Xi Luo, et al. "Phylogeny of Phyllachora species on bamboo and P. cephalostachyi sp. nov. from China." Phytotaxa 514, no. 2 (2021): 158–66. https://doi.org/10.11646/phytotaxa.514.2.7.

Full text

Abstract:

Li, Xiao-Ling, Yu, Hai-Ying, Luo, Xi, Wu, Hao, Zhao, Chun-Yan, Promputtha, Itthayakorn, Sun, Da-Feng (2021): Phylogeny of Phyllachora species on bamboo and P. cephalostachyi sp. nov. from China. Phytotaxa 514 (2): 158-166, DOI: 10.11646/phytotaxa.514.2.7, URL: http://dx.doi.org/10.11646/phytotaxa.514.2.7

APA, Harvard, Vancouver, ISO, and other styles

2

Han, Han, Xiaofeng Yang, Ying Zhao, et al. "Abstract 504: BPI-472372: a potent and orally bioavailable small molecule inhibitor of CD73 for cancer immunotherapy." Cancer Research 83, no. 7_Supplement (2023): 504. http://dx.doi.org/10.1158/1538-7445.am2023-504.

Full text

Abstract:

Abstract CD73, also known as ecto-5'-nucleotidase, plays a major role in converting extracellular adenosine monophosphate (AMP) to immunosuppressive adenosine. It is frequently overexpressed across a variety of cancers. High adenosine level in the tumor microenvironment, predominantly signaling through the A2a/A2b receptors, suppresses innate and adaptive immune responses and mediates tumor immune evasion. CD73 overexpression is correlated with poor prognosis in several tumor types. Inhibition of CD73 to reduce adenosine production is a promising therapeutic approach for the treatment of cance

APA, Harvard, Vancouver, ISO, and other styles

3

Li, Zhengqing, Renqi Xu, Xiaofeng Yang, et al. "Abstract 6513: Discovery and characterization of a KRASG12C/D/V degrader with potent anti-tumor activity in KRASmut-driven preclinical models." Cancer Research 84, no. 6_Supplement (2024): 6513. http://dx.doi.org/10.1158/1538-7445.am2024-6513.

Full text

Abstract:

Abstract KRAS mutations are one of the most common oncogenic drivers for multiple cancers. KRASG12X mutations are identified in approximately 25% of lung cancer, 24% of colorectal (CRC), and 79% of pancreatic ductal adenocarcinoma (PDAC). Although the approval of Sotorasib in 2021 by the FDA partially addressed the needs of patients with KRASG12C mutant, other mutations, such as G12D and G12V, still lack effective target therapies. Here, we report RD0255359, a proteolysis targeting chimera (PROTAC) KRASG12C/D/V degrader with highly potent cell viability and KRASG12C/D/V degradation ability. In

APA, Harvard, Vancouver, ISO, and other styles

4

Yang, Xiang, Xiaoguan Zhu, Han Han, et al. "Abstract 4379: BPI-572270: An orally bioavailable and highly potent RAS (On) multi tri-complex inhibitor." Cancer Research 85, no. 8_Supplement_1 (2025): 4379. https://doi.org/10.1158/1538-7445.am2025-4379.

Full text

Abstract:

Abstract KRAS mutations are oncogenic drivers occur in approximately 20%-30% of all cancers with particularly high frequencies observed in pancreatic cancer (∼90%), non-small cell lung cancer (∼35%), and colorectal cancer (∼45%). While approved KRASG12C inhibitors have demonstrated clinical benefits in patients with KARSG12C mutation, other prevalent KRAS mutations, such as KRASG12D/G12V/G13D/Q61H, remain a significant therapeutic challenge. Here we present BPI-572270, a highly potent Cyclophilin A-dependent RAS(On)multi inhibitor with favorable oral bioavailability designed to target those di

APA, Harvard, Vancouver, ISO, and other styles

5

Li, Qiao, Xian Wang, Ying Cheng, et al. "Abstract P4-01-07: FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study." Cancer Research 83, no. 5_Supplement (2023): P4–01–07—P4–01–07. http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-01-07.

Full text

Abstract:

Abstract Background: FS-1502 is a HER2-targeting antibody drug-conjugate with a cleavable β-glucuronide linker and an antimitotic agent (monomethyl auristatin F) which showed promising antitumor activity in preclinical studies. We are evaluating the safety and tolerability of FS-1502 in patients with HER2-expressing advanced solid tumors (NCT03944499). Methods: Patients with HER2-expresssing advanced solid tumors who had failed prior standard of care therapies were enrolled in a single-arm, open-label, dose-escalation phase Ia study in China. FS-1502 was given IV once in 21-day or 28-day cycle

APA, Harvard, Vancouver, ISO, and other styles

6

Wu, Dong, Ying Qing, Keith Leung, et al. "Abstract 1035: Western lifestyle leads to obesity and cancer via a common factor FTO." Cancer Research 85, no. 8_Supplement_1 (2025): 1035. https://doi.org/10.1158/1538-7445.am2025-1035.

Full text

Abstract:

Abstract FTO, the first identified RNA N6-methyladenosine (m6A) demethylase, has been reported by our group to play an oncogenic role in acute myeloid leukemia (AML) and by others in various solid tumors, including colorectal and liver cancers. Additionally, FTO was the first gene identified through genome-wide association studies (GWAS) to be associated with obesity risk, with evidence linking elevated FTO expression to increased food intake and obesity development. While obesity is a recognized risk factor for cancer, whether FTO serves as a shared factor driving both obesity and cancer rema

APA, Harvard, Vancouver, ISO, and other styles

7

Qing, Ying, Dong Wu, Yangchan Li, et al. "Abstract 4843: TET2 oxidizes chromatin-associated regulatory RNA m5C to potentiate anti-tumor immunity." Cancer Research 85, no. 8_Supplement_1 (2025): 4843. https://doi.org/10.1158/1538-7445.am2025-4843.

Full text

Abstract:

Current immunotherapies have shown limited success in treating acute myeloid leukemia (AML) due to immune evasion, which often stems from epigenetic dysregulation of immune-related pathways. TET2, a well-studied DNA 5-methylcytosine dioxygenase, is frequently mutated and recognized as a tumor suppressor in AML. While TET2 deficiency in hematopoietic stem/progenitor cells (HSPCs) has been associated with elevated inflammation, TET2 has also been reported to promote inflammatory interferon (IFN) signaling in solid tumors, enhancing tumor responses to immunotherapies. Despite these findings, the

APA, Harvard, Vancouver, ISO, and other styles

8

Yao, Herui, Min Yan, Zhongsheng Tong, et al. "Abstract PS8-08: Efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations: a global, multi-center, first-in-human, phase 1 study." Clinical Cancer Research 31, no. 12_Supplement (2025): PS8–08—PS8–08. https://doi.org/10.1158/1557-3265.sabcs24-ps8-08.

Full text

Abstract:

Abstract Background: SHR-A1811, an anti-HER2 ADC comprising trastuzumab, a cleavable linker, and the topoisomerase I inhibitor payload SHR169265, has shown substantial tumor response and a manageable safety profile in heavily treated multiple solid tumors with HER2 expression or mutations (Yao. et al., JCO, 2024). Here we present for the first time the progression-free survival (PFS) analysis results of SHR-A1811 and updated safety results, including an additional 1-year of follow-up and an expanded cohort from 307 to 391 patients. Methods: Patients eligible for this study had HER2-expressing

APA, Harvard, Vancouver, ISO, and other styles

9

Liu, Xiyu, Ying Xu, Xiuzhi Zhu, et al. "Abstract PS3-01: Tislelizumab plus sitravatinib and nab-paclitaxel in patients with untreated locally recurrent or metastatic triple negative breast cancer (TNBC): updated efficacy and safety results." Clinical Cancer Research 31, no. 12_Supplement (2025): PS3–01—PS3–01. https://doi.org/10.1158/1557-3265.sabcs24-ps3-01.

Full text

Abstract:

Abstract Background: The PD-(L)1 inhibitor-chemotherapy combination has established efficacy as first-line treatment for PD-L1 positive metastatic TNBC, but novel treatment regimens are still needed to improve the clinical outcomes for the whole population of TNBC in the first-line setting. Emerging evidence indicates that the combination of anti-angiogenic therapies and PD-(L)1 blockade may act synergistically, thereby potentiating enhanced antitumor activity. Sitravatinib (Sitra) is a spectrum-selective tyrosine kinase inhibitor that could potently inhibit split kinase receptors and TAM rece

APA, Harvard, Vancouver, ISO, and other styles

10

Amin, Adam Aliathun, and Eva Imania Eliasa. "Parenting Skills as The Closest Teacher to Early Childhood at Home." JPUD - Jurnal Pendidikan Usia Dini 17, no. 2 (2023): 312–30. http://dx.doi.org/10.21009/jpud.172.09.

Full text

Abstract:

Parents play an important role in the development of their children. This research reflects the role of parents in developing children. Through four stages of identification, screening, eligibility, and acceptable results, this method uses a systematic literature review using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) method. The findings from the fourteen articles examined show that parenting skills play an important role in a child's growth and development from birth to death. The determining factor in the development of physical, motoric, moral, language

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Ying han dui zhao du wu"

1

qian, Wu yu, and Du miao. Ying han · han ying jia duan shang xi. Zhong guo cheng shi chu ban she, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Suogeluo, Aotuo. Pang guo wang: Ying han dui zhao. Tian di chu ban she, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

yun, Yi. Ying han dui zhao sheng huo xiao pin. Wen hui chu ban she, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Yi, Suo. Yi suo yu yan: Ying han dui zhao. Hai tian chu ban she, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Sun, Zhili, Jun Wu, and Yahui Tong. Mei guo jia ting zong heng: Ying han dui zhao. Hua zhong li gong da xue chu ban she, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Jingyang, Wang. Ma zui xin gai nian: Han ying dui zhao. Fu dan da xue chu ban she, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Fu, Erman. A li ge la zhi mi: [ Ying han dui zhao ]. Wai yu jiao xue yu yan jiu chu ban she, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sarah. Shi qu de ji yi: Ying han dui zhao. Wai yu jiao xue yu yan jiu chu ban she, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Le, Qi. Dang dai ying mei you mo jing pin: Ying han dui zhao : Shi sheng pian. Tian jin ke ji fan yi chu ban gong si, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Zhang, Hua. Nei xie guang ying fei hua de mei huo. Shan xi shi fan da xue chu ban she, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!